Table 3.
Linear Mixed Models Results for Functioning Outcomes Over Time Following Treatment as Predicted from 1‐ and 2‐Level Reductions Over Time (n = 1,226) and Sensitivity Analyses with Missing = Failure Imputation (n = 1,226) and Excluding Abstainers (n = 1,052)
| SBP (mm/Hg) | AST (IU/l) | ALT (IU/l) | GGT (IU/l) | DrInC | PHDD | PDD | DPDD | |
|---|---|---|---|---|---|---|---|---|
| B (SE) | B (SE) | B (SE) | B (SE) | B (SE) | B (SE) | B (SE) | B (SE) | |
| Linear mixed models | ||||||||
| 1‐level reduction | −6.42 (1.11)*** | −7.87 (2.18)*** | −6.33 (2.09)*** | −26.92 (10.47)* | −19.24 (1.32)*** | −39.89 (1.76)*** | −32.69 (1.62)*** | −4.86 (0.36)*** |
| 2‐level reduction | −6.00 (0.84)*** | −7.19 (1.55)*** | −6.00 (1.53)*** | −21.84 (7.97)** | −17.40 (1.08)*** | −38.55 (1.45)*** | −33.65 (1.39)*** | −4.16 (0.28)*** |
| Missing = failure models | ||||||||
| 1‐level reduction | −5.69 (1.09)*** | −7.62 (2.09)*** | −6.12 (2.01) ** | −25.60 (10.07)* | −18.21 (1.27)*** | −29.71 (1.62)*** | −24.53 (1.49)*** | −3.23 (0.31)*** |
| 2‐level reduction | −5.56 (0.84)*** | −7.13 (1.53)*** | −5.86 (1.50)*** | −21.37 (7.67) ** | −16.84 (1.06)*** | −32.07 (1.41)*** | −28.37 (1.33)*** | −3.25 (0.26)*** |
| Excluding abstainers | ||||||||
| 1‐level reduction | −5.14 (1.13)*** | −6.36 (2.15)** | −4.17 (1.99)* | −12.64 (6.82) | −14.39 (1.22)*** | −38.27 (1.77)*** | −28.10 (1.63)*** | −3.54 (0.41)*** |
| 2‐level reduction | −4.26 (0.89)*** | −5.49 (1.60)** | −3.87 (1.56)* | −8.24 (5.21) | −13.14 (1.02)*** | −38.19 (1.54)*** | −29.34 (1.45)*** | −2.96 (0.33)*** |
B (SE) = unstandardized regression coefficients (standard error), which can be interpreted as the decrease in outcomes based on achieving at least a 1‐ and 2‐level reduction, at the average of all covariates (covariate effects reported in Table S1); AST, aspartate aminotransferase; ALT, alanine aminotransferase; DPDD, drinks per drinking day; DrInC, Drinker Inventory of Consequences Total Score; GGT, γ‐glutamyltransferase; IU/l, international units per liter; PDD, percent drinking days; PHDD, percent heavy drinking days; SBP, systolic blood pressure. The reference group for the 1‐level reduction was no change or an increase in the WHO risk drinking level from baseline to the treatment/follow‐up months, and the reference group for the 2‐level reduction was the 1‐level reduction, no change, or increase in the WHO risk level from baseline to the treatment/follow‐up months.
*p < 0.05, **p < 0.01, ***p < 0.001.